Grifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Book value per share
Grifols, S.A.'s book value per share at the end of fiscal 2025 was 12.6×, down 7.76% from 13.7× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 0.0×. Over the past ten years it has ranged from 5.3× (fiscal 2015) to 27.2× (fiscal 2022); the current reading is higher than 50% of that period. Grifols, S.A. ranks 17th of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 12.6× | (7.76%) |
| FY2024 | 13.7× | 7.95% |
| FY2023 | 12.7× | (3.16%) |
| FY2022 | 13.1× | (51.81%) |
| FY2022 | 27.2× | 114.14% |
| FY2021 | 12.7× | (52.23%) |
| FY2021 | 26.6× | 137.45% |
| FY2020 | 11.2× | (49.52%) |
| FY2020 | 22.2× | 98.20% |
| FY2019 | 11.2× | (47.76%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 12.6× | — |
| 31 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BIIB Biogen Inc. compare | 128× |
| SNY Sanofi compare | 35.1× |
| AMRN Amarin Corporation PLC compare | 21.3× |
| GSK GSK PLC Sponsored ADR compare | 12.3× |
| BMY Bristol Myers Squibb Company compare | 11.5× |
| NVO Novo Nordisk A/S compare | 7.6× |
| OGN Organon & Co. compare | 4.5× |
| GRFS Grifols, S.A. | 0.0× |
| NSRX Nasus Pharma Ltd. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement